QC
IOVA icon

Quadrature Capital’s Iovance Biotherapeutics IOVA Stock Holding History

Quadrature Capital’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.16M Buy
278,937
+120,008
+76% +$456K 0.01% 692
2026
Q1 		$558K Sell
158,929
-159,774
-50% -$511K 0.01% 755
2025
Q4 		$870K Buy
+318,703
New +$737K 0.01% 556
2025
Q3 		– Sell
-144,124
Closed -$247K – 1258
2025
Q2 		$247K Buy
144,124
+111,392
+340% +$277K ﹤0.01% 748
2025
Q1 		$109K Buy
+32,732
New +$169K ﹤0.01% 928

Other funds holding IOVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Quadrature Capital's IOVA Position: Q2 2026 in Review

Quadrature Capital increased its Iovance Biotherapeutics (IOVA) stake by 76% in Q2 2026, buying an estimated $456K and bringing the position to 278,937 shares worth $1.16M. The position accounts for 0.01% of the portfolio, ranked #692.

Quadrature Capital first reported a position in IOVA in Q1 2025 and has held it in 5 quarters since. 292 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.

  • Quadrature Capital held 278,937 shares of Iovance Biotherapeutics worth $1.16M as of Q2 2026.
  • Quadrature Capital bought 120,008 Iovance Biotherapeutics shares in Q2 2026, an estimated $456K.
  • Iovance Biotherapeutics made up 0.01% of Quadrature Capital's portfolio in Q2 2026, its #692 holding.
  • Quadrature Capital first reported a position in Iovance Biotherapeutics in Q1 2025 and has held it in 5 quarters since.
  • 292 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.

Based on Quadrature Capital's 13F filing for Q2 2026, filed 7 Aug 2026.